Short Term Stocks To Buy Based on Stock Algorithm: Returns up to 14.99% in –

Short Term Stocks To Buy

This forecast is part of the Top 10 Stocks Package, as one of I Know First’s systematic trading tools. The full package includes a daily prediction for a total of 20 short term stocks to buy or sell:

  • Top 10 stocks pick for the long position
  • Top 10 stocks pick for the short position

Package Name: Top 10 Stocks
Recommended Positions: Long
Forecast Length: – (05/27/2018 – 06/04/2018)
I Know First Average: 3.43%
Short Term Stocks To Buy

The algorithm correctly predicted 7 out 10 of the suggested trades in the Top 10 Stocks Package for this – forecast. FMI was the highest-earning trade with a return of 14.99% in -. Additional high returns came from WSM and TIF, at 10.38% and 3.41% respectively. The package had an overall average return of 3.43%, providing investors with a 2.49% premium over the S&P 500’s return of 0.94% during the period.

Foundation Medicine, Inc., incorporated on November 12, 2009, is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company is engaged in the business of delivering molecular information about cancer to its customers. The Company’s platform includes various methods and algorithms for analyzing specimens across various types of cancer, and for incorporating that information into clinical care. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).

As of December 31, 2016, FoundationOne assessed 315 biologically relevant cancer genes for all classes of genomic alterations with sensitivity and specificity. The Company’s FoundationICE is an online interactive cancer explorer and allows physicians to access the genomic information identified by its products along with information about the reported genomic alterations, associated therapies and clinical trials. FoundationICE presents genomic information in an interface that links directly into publicly available databases, such as PubMed and, to provide additional information relevant to a patient’s identified genomic alterations. The Company’s FoundationCORE is its knowledgebase that includes genomic data, medical and scientific literature, clinical trial information, and a small but growing amount of clinical outcome information. FoundationCORE powers FoundationICE, enabling oncologists and pathologists in clinical practice to utilize this aggregated data set to collaborate and share treatment choices, response rates and other clinical information in the Health Insurance Portability and Accountability Act (HIPAA)-compliant manner. Each FoundationOne, FoundationOne Heme and FoundationACT analysis consists of three parts: specimen preparation, sequencing, and data analysis and reporting.

The Company competes with Bio-Reference Laboratories, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Caris Life Sciences, Guardant Health, Paradigm, NeoGenomics Laboratories, Abbott Laboratories, Qiagen N.V., Sequenom, Inc., Genomic Health, Inc., Myriad Genetics, Inc., Illumina, Thermo Fisher Scientific, Inc., Biocept, Exosome Diagnostics, Inivata, Personal Genome Diagnostics and Roche Diagnostics.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.